Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East

被引:8
作者
Matsubara, Nobuaki [1 ]
Mukai, Hirofumi [1 ]
Nagai, Shunji [1 ]
Itoh, Kuniaki [1 ]
机构
[1] Natl Canc Ctr Hosp E, Div Hematol & Oncol, Chiba 2778577, Japan
关键词
Unknown primary; Unknown origin; Cancer; Diagnosis; Treatment; PRIMARY SITE; PRIMARY TUMORS; COMBINATION CHEMOTHERAPY; CARCINOMA; CLASSIFICATION; EPIDEMIOLOGY; MANAGEMENT; CISPLATIN; SURVIVAL; ORIGIN;
D O I
10.1007/s10147-010-0112-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary unknown cancer (PUC) is not rare neoplasm. The clinical features and survival time of these patients are heterogeneous. We analyzed cases that were referred to the National Cancer Center Hospital East with preliminary diagnosed PUC to evaluate the natural history and clinical features. We retrospectively reviewed medical records of PUC patients who were referred to our institution between August 2005 and December 2008. One hundred and twenty-six patients with preliminary diagnoses of PUC were referred to the National Cancer Center Hospital East from community hospitals. The median age was 63 years (range 31-89 years). Almost all patients (85.7%) had good performance status (0-1). The mean interval between the first visit to a community hospital and referral to our hospital was 3.66 months (range 0-60 months). In 41 patients (32.5%), primary malignancies were identified by immunohistochemical studies and radiographical workup after referral to our hospital. Twenty-eight patients (22.2%) were defined as belonging to favorable subsets. About 50% of patients with unfavorable subsets received chemotherapy. None of the patients were autopsied. In about half of the patients with preliminary diagnosed PUC, the primary origin could be identified, or it was possible to distinguish subsets with favorable prognosis.
引用
收藏
页码:578 / 582
页数:5
相关论文
共 20 条
[1]   UNKNOWN PRIMARY-CARCINOMA - NATURAL-HISTORY AND PROGNOSTIC FACTORS IN 657 CONSECUTIVE PATIENTS [J].
ABBRUZZESE, JL ;
ABBRUZZESE, MC ;
HESS, KR ;
RABER, MN ;
LENZI, R ;
FROST, P .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1272-1280
[2]  
ALTMAN E, 1986, CANCER-AM CANCER SOC, V57, P120, DOI 10.1002/1097-0142(19860101)57:1<120::AID-CNCR2820570124>3.0.CO
[3]  
2-M
[4]   Multi-platform, multi-site, microarray-based human tumor classification [J].
Bloom, G ;
Yang, IV ;
Boulware, D ;
Kwong, KY ;
Coppola, D ;
Eschrich, S ;
Quackenbush, J ;
Yeatman, TJ .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :9-16
[5]   Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) [J].
Bugat, R ;
Bataillard, A ;
Lesimple, T ;
Voigt, JJ ;
Culine, S ;
Lortholary, A ;
Merrouche, Y ;
Ganem, G ;
Kaminsky, MC ;
Negrier, S ;
Perol, M ;
Laforêt, C ;
Bedossa, P ;
Bertrand, G ;
Coindre, JM ;
Fizazi, K .
BRITISH JOURNAL OF CANCER, 2003, 89 (Suppl 1) :S59-S66
[6]   Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site [J].
Culine, S ;
Kramar, A ;
Saghatchian, M ;
Bugat, R ;
Lesimple, T ;
Lortholary, A ;
Merrouche, Y ;
Laplanche, A ;
Fizazi, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4679-4683
[7]   LACK OF VALUE FOR CISPLATIN ADDED TO MITOMYCIN-DOXORUBICIN COMBINATION CHEMOTHERAPY FOR CARCINOMA OF UNKNOWN PRIMARY SITE - A RANDOMIZED TRIAL [J].
EAGAN, RT ;
THERNEAU, TM ;
RUBIN, J ;
LONG, HJ ;
SCHUTT, AJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1987, 10 (01) :82-85
[8]   Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin [J].
Falkson, CI ;
Cohen, GL .
ONCOLOGY, 1998, 55 (02) :116-121
[9]   Unknown primary tumours [J].
Hillen, HFP .
POSTGRADUATE MEDICAL JOURNAL, 2000, 76 (901) :690-693
[10]   Epidemiology of unknown primary tumours [J].
Levi, F ;
Te, VC ;
Erler, G ;
Randimbison, L ;
La Vecchia, C .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (13) :1810-1812